We studied serum phospho-CSE1L for assaying the efficacy of targeted therapy using mice melanoma and colorectal tumor xenograft models and drugs including vemurafenib, sorafenib, sunitinib, and lapatinib. This evidence concerns the gene CSE1L and colorectal neoplasm.